학술논문
Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).
Document Type
Article
Author
Rescigno, Pasquale; Fenor de la Maza, Maria Dolores; Burnett, Stephanie M.; Villacampa, Guillermo; Stiles, Morgaine; Cafferty, Fay Helen; Beije, Nick; Carreira, Suzanne; Figueiredo, Ines; Flohr, Penelope; Gurel, Bora; Bertan, Claudia; Westaby, Daniel; Chandran, Khobe; Crespo, Mateus; Perna, Carla; Tunariu, Nina; Sharp, Adam; Yap, Christina; De Bono, Johann S.
Source
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p138-138, 235p
Subject
Language
ISSN
0732183X